JAMES C YAO to United States
This is a "connection" page, showing publications JAMES C YAO has written about United States.
Connection Strength
0.451
-
Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer. 2018 02 15; 124(4):807-815.
Score: 0.044
-
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 Oct 01; 3(10):1335-1342.
Score: 0.043
-
Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial. Pancreas. 2015 Mar; 44(2):181-9.
Score: 0.036
-
Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis. Cancer. 2014 Jul 01; 120(13):2039-49.
Score: 0.034
-
Accelerated approval and breakthrough therapy designation: oncology drug development on speed? Clin Cancer Res. 2013 Aug 15; 19(16):4305-8.
Score: 0.032
-
Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas. 2012 Apr; 41(3):461-6.
Score: 0.030
-
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011 Mar 01; 29(7):934-43.
Score: 0.027
-
Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study. Int J Cancer. 2008 Aug 15; 123(4):867-73.
Score: 0.023
-
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun 20; 26(18):3063-72.
Score: 0.023
-
Population-based study of islet cell carcinoma. Ann Surg Oncol. 2007 Dec; 14(12):3492-500.
Score: 0.022
-
Effects of sex and racial/ethnic group on the pattern of gastric cancer localization. Gastric Cancer. 2002; 5(4):208-12.
Score: 0.015
-
Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database. Pancreas. 2021 04 01; 50(4):506-512.
Score: 0.014
-
Racial Differences in the Incidence and Survival of Patients With Neuroendocrine Tumors. Pancreas. 2019 Nov/Dec; 48(10):1373-1379.
Score: 0.012
-
Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clin Cancer Res. 2019 10 15; 25(20):6107-6118.
Score: 0.012
-
Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors. Pharmacoeconomics. 2018 08; 36(8):1005-1013.
Score: 0.011
-
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. J Natl Compr Canc Netw. 2018 06; 16(6):693-702.
Score: 0.011
-
Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States. Oncology. 2017; 93(4):233-242.
Score: 0.011
-
Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. Oncologist. 2017 12; 22(12):1451-1462.
Score: 0.011
-
Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement. Clin Cancer Res. 2017 Mar 15; 23(6):1414-1421.
Score: 0.010
-
What's in a Name? Steady Progress in Staging Pancreatic Neuroendocrine Tumors. J Clin Oncol. 2017 01 20; 35(3):265-267.
Score: 0.010
-
Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. J Natl Cancer Inst. 2013 Jul 03; 105(13):954-9.
Score: 0.008
-
Characteristics of Epstein-Barr virus-associated gastric cancer: a study of 235 cases at a comprehensive cancer center in U.S.A. J Exp Clin Cancer Res. 2009 Feb 03; 28:14.
Score: 0.006
-
The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinoma. Results from the National Cancer Data Base. Cancer. 2008 Aug 01; 113(3):461-9.
Score: 0.006